Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Relievant Medsystems, founded in 2006 and headquartered in Edina, Minnesota, is a commercial-stage medical device company specializing in the diagnosis and treatment of vertebrogenic pain. The company's flagship product, the Intracept system, is a minimally invasive procedure that delivers targeted energy into the spine to block pain signals from the basivertebral nerve.
Since its inception, Relievant Medsystems has raised a total of $273.6 million in funding, demonstrating significant investor interest in its innovative medical technology. The company's focus on addressing chronic back pain, a widespread health issue, positions it as a potentially attractive investment opportunity in the healthcare sector.
In September 2023, Boston Scientific acquired Relievant Medsystems for an undisclosed amount, with additional contingent payments based on sales performance over the next three years. This acquisition marks a significant milestone for Relievant Medsystems and may impact any previous considerations for an initial public offering (IPO).
Given the recent acquisition by Boston Scientific, the likelihood of Relievant Medsystems pursuing an IPO in the near future is uncertain. As a subsidiary of a publicly traded company, Relievant Medsystems' financial performance will likely be reflected in Boston Scientific's reports moving forward. Investors interested in gaining exposure to Relievant Medsystems' technology and market potential may consider exploring investment opportunities in Boston Scientific stock.
We at Linqto strive to provide our clients with access to promising private investment opportunities. While Relievant Medsystems is no longer a candidate for direct private investment due to its acquisition, we continue to monitor the medical device and healthcare sectors for similar high-potential companies that may offer attractive investment prospects.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Relievant Medsystems' IPO prospects remain uncertain, investors interested in innovative medical technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the healthcare and medical device sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging medical technology firms before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
